Galectin Therapeutics (NASDAQ:GALT), a clinical-stage biotech firm focused on liver fibrosis and cancer, reported its second quarter 2025 results on August 14, 2025. The most significant news was a lower-than-expected GAAP loss per share of $0.12 and reduced expenses as Galectin advanced its NAVIGATE trial for belapectin, an investigational therapy for MASH cirrhosis. GAAP net loss per share was ($0.12), outperforming analyst GAAP EPS estimates of ($0.16). This improvement stems largely from lower research and development spending following a key clinical milestone. There was no revenue. Overall, the company tightened costs following the main phase of its flagship trial, maintained enough liquidity for near-term activities, and updated investors on progress toward strategic and regulatory goals.

Source: Analyst estimates for the quarter provided by FactSet.

Galectin Therapeutics is a biotechnology company developing novel therapies that target galectins, which are proteins linked to immune and fibrotic diseases. Its main program is belapectin, an intravenous galectin-3 inhibitor drug candidate being tested as a potential treatment for patients with cirrhosis due to metabolic dysfunction-associated steatohepatitis (MASH, formerly known as NASH), especially those at risk of esophageal varices, which are dangerous vein enlargements in the esophagus caused by advanced liver disease.

Continue reading

Source Fool.com